Mohammad Jahangiri
Neurology · Los Angeles, CANPI 1174142202
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.
Across 109 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$607
- UCB, Inc.$530
- SK Life Science, Inc.$350
- Takeda Pharmaceuticals U.S.A., Inc.$237
- Genentech USA, Inc.$197
- Argenx US, Inc.$115
- plus $921 from 17 others
What the payments were for
- Food & beverage$2,958100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $607 |
| UCB, Inc. | 17 | $530 |
| SK Life Science, Inc. | 12 | $350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $237 |
| Genentech USA, Inc. | 7 | $197 |
| Argenx US, Inc. | 4 | $115 |
| Jazz Pharmaceuticals Inc. | 5 | $112 |
| Acadia Pharmaceuticals Inc | 5 | $108 |
| Tanabe Pharma America, Inc. | 6 | $98 |
| AbbVie | 4 | $92 |
| Novartis | 4 | $92 |
| Upsher-smith Laboratories LLC | 3 | $68 |
| Biogen | 4 | $67 |
| Eisai Inc. | 3 | $60 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Neurelis, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Immedica Pharma US, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HYQVIA$122
How this compares
$2,958 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 32 | $4,925 |
| Levetiracetam | 29 | $1,458 |
| Divalproex Sodium | 13 | $248 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.